Terkko Navigator / Lancet Oncology

Correction to Lancet Oncol 2020; 21: 808–20

Radiation-induced angiosarcoma in a patient with breast cancer

Cancer registration in China and its role in cancer prevention and control

Expanding access to radiotherapy in sub-Saharan Africa

Carcinogenicity of some aromatic amines and related compounds

Lenvatinib and pembrolizumab in advanced gastric cancer

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Cancer and the microbiome

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Racism, discrimination, and the practice of oncology

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus

New advances in prostate cancer screening and monitoring

2020 ASCO Virtual Annual Meeting

A new approach to refractory gastrointestinal stromal tumours with diverse acquired mutations

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Developing anti-CD19 antibody-based combinations in lymphoma

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Knowing your tumour?

Sister Mary Joseph nodule in mantle cell lymphoma

Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Poor clinical outcomes for patients with cancer during the COVID-19 pandemic

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Optimal goal of management of delirium in end-of-life cancer care

Lockdown poses new challenges for cancer care in India

COVID-19: consequences for higher education

Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America

Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Towards greater clarity in the treatment of cholangiocarcinoma

Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Correction to Lancet Oncol 2020; published online April 30. https://doi.org/10.1016/S1470-2045(20)30265-5

Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial

New mitomycin formulation for low-grade upper tract urothelial cancer

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

CDK4/6 inhibition in HER2-positive breast cancer

COVID-19: impact on cancer workforce and delivery of care

Platinum-sensitive ovarian cancer: liminal advances

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19

Taking care of older patients with cancer in the context of COVID-19 pandemic

CAR T-cell therapy for relapsed or refractory mantle-cell lymphoma